In its first major move of 2026, Amgen (NASDAQ: AMGN) has announced the acquisition of Dark Blue Therapeutics Ltd., a privately held U.K. biotech specializing in precision oncology. The deal, valued at up to $840 million, underscores Amgen’s commitment to “targeted protein degradation” as a cornerstone of its next-generation cancer strategy.
A New Weapon Against Acute Myeloid Leukemia
The centerpiece of the acquisition is DBT-3757, a first-in-class, small-molecule degrader currently in the final stages of preclinical development. The molecule is designed to target and destroy MLLT1 and MLLT3, two proteins known to drive the progression of specific, aggressive subtypes of Acute Myeloid Leukemia (AML).
AML remains one of the most challenging blood cancers to treat, often characterized by rapid progression and high rates of resistance to standard therapies. Preclinical data suggest that DBT-3757 not only exhibits potent anti-cancer activity but also offers a “mechanistic differentiation” from existing treatments. This unique profile provides a strong rationale for its use as both a standalone therapy and in combination with current standard-of-care drugs to prevent relapse.
Strategic Rationale: Beyond the Patent Cliff
For Amgen, the acquisition is a calculated step to bolster its oncology pipeline as it prepares for a more competitive landscape later this decade. With top revenue generators like Prolia and Kyprolis facing upcoming patent expirations, Amgen is aggressively investing in high-potential, early-stage assets.
Read More: Amgen Announces $900 Million Worth Expansion of Manufacturing Facility in the US
From Oxford Spin-out to Global Integration
Founded in 2020 as a spin-out from the University of Oxford, Dark Blue Therapeutics quickly gained industry attention. The company emerged with a £75 million Series A round in 2022, backed by heavyweights including Oxford Science Enterprises, Forbion, and Bristol Myers Squibb.
Under the terms of the agreement, Dark Blue’s board will step down, and its 18-person team and research operations will be integrated into Amgen’s global R&D organization. Amgen plans to leverage its vast clinical development expertise to propel DBT-3757 into human trials.
GSK Secures Japan Orphan Drug Designation for Risvutatug Rezetecan in Small-Cell Lung Cancer
GSK’s risvutatug rezetecan has officially secured Orphan Drug Designation from Japan’s MHLW for the treatment of small-cell lung cancer (SCLC). Supported by durable response data […]
Industry Impact
The deal highlights a growing trend of “big pharma” looking toward the U.K.’s “Golden Triangle” (Oxford, Cambridge, London) for breakthrough innovations in epigenetics and protein degradation. By acquiring Dark Blue, Amgen not only secures a promising AML candidate but also gains proprietary insights into the YEATS domain a critical area of cancer biology that may hold the key to treating various solid tumors.
As the transaction closes, the biotech industry will be watching closely for the first clinical data from the MLLT1/3 program, which could represent a significant milestone for patients facing a challenging AML diagnosis.
Last Modified:
